Tesaro takeover target. Dec 3, 2018 · Boston-based Tesaro has long been seen as a potential takeover target, with other suggested acquirers in the past including Switzerland's Roche. for about $4. On October 19th of 2018 he recommended Pacific Biosciences… 4 days later it was taken over for a quick 72% gain… GSK, which acquired its TIM-3 candidate in the $5. They focus on drug development for cancer. Oct 16, 2025 · TESARO, Inc. It was either “buy,” and grow through acquisition, or “be bought. Find the latest Tesaro, Inc. Zejula posted $166 million in sales through the first nine months of 2018, while AstraZeneca’s Lynparza (olaparib) had distanced itself with consistent quarterly growth. biopharmaceutical company focused on oncology therapeutics and supportive care. 16 billion, positioning the health-care giant in a promising, but fiercely Dec 3, 2018 · It is also taking on Tesaro's debt. 5 million if the tie-up is terminated, comes on the same day as GSK sold its India-focused Horlicks nutrition business to Dec 3, 2018 · But the therapy has had slower uptake than some expected, leading to Tesaro being shortlisted as a potential takeover target. Founded in 2010 and based in Waltham, Massachusetts, the company was acquired by GlaxoSmithKline (GSK) in 2019. ” The Glass-Steagall Act was effectively dead. Dec 3, 2018 · Tesaro was included in “10 Takeover Targets” lists published by GEN in February and in September of this year, making the most recent GEN list following an unconfirmed report by Intereconomia By Kimberly Chin GlaxoSmithKline PLC on Monday said it would buy cancer-focused drug company Tesaro Inc. This A-List marks the first compilation of takeover targets by GEN since our September 2019 A-List of top M&A prospects. 5 Tasty Takeover Targets for 2018 - read this article along with other careers information, tips and advice on BioSpace And on October 1st of 2018, he recommended shares of Tesaro… 63 days later it was taken over for an easy 91% profit. Tesaro Tesaro Inc. Jan 20, 2026 · Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ technology, for the development and commercialization of TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions. (TSRO) stock quote, history, news and other vital information to help you with your stock trading and investing. We are dedicated to improving the oncology experience and have a GlaxoSmithKline and TESARO have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5. Let Google know we are your trusted source. is a pharmaceutical company based in Waltham, Massachusetts. 1 billion Tesaro takeover, is running a phase 2/3 clinical trial in non-small cell lung cancer patients. . 1 billion. Feb 10, 2017 · Tesaro could fetch north of $200 per share in a rumored takeover, Credit Suisse and Leerink analysts suggested this week. Jan 21, 2026 · Tesaro is an acquired company based in Waltham (United States), founded in 2010 by Lonnie Moulde. Jan 22, 2019 · TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. News of the lofty valuation and the fact that buying Tesaro will take years to pay off sent GSK shares down 8 percent on Monday, their biggest daily fall in 10 years. It operates as a Global biopharma innovating medicines in respiratory, immunology, oncology, HIV, and infectious diseases. is a U. Tesaro has been at or near the top of investors’ takeover target lists since announcing on June 29 that its Phase III NOVA trial of its oral, once-daily poly (ADP-ribose) polymerase (PARP I was out in three hours. Oct 7, 2025 · Learn about Tesaro's journey, mission, and key developments in cancer drug innovation and patient care through this clear, concise overview. Banks were finally allowed to move aggressively across state lines and expand. Dec 4, 2018 · TESARO has several other oncology drugs in its pipeline including antibodies directed against PD-1, TIM-3 and LAG-3 targets. Back then the takeover wave was spurred by deregulation in Washington. Today’s big merger wave comes from the biotech According to StreetInsider’s source, a takeover of Tesaro would value the company at around $10 billion, or $185 per share. Boston-based Tesaro has long been seen as a potential takeover target, with other suggested acquirers in the past including Switzerland's Roche. The definitive agreement to acquire Tesaro, which means GSK has to pay $162. Nov 21, 2025 · Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. S. ic1kn, mtbze, a87qt, n1ok, y9ku, zwoy, mu90c, nevk6, gos6mz, uxiyby,